LOS ANGELES--(BUSINESS WIRE)--The sixth paragraph of the release has been replaced.
The updated release reads:
TARO INVESTORS HAVE OPPORTUNITY TO LEAD TARO PHARMACEUTICAL INDUSTRIES LTD. SECURITIES FRAUD LAWSUIT WITH THE SCHALL LAW FIRM
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”) (NYSE: TARO) for violations of the federal securities laws.
Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Documents in connection with its initial public offering (“IPO”) conducted on or about January 25, 2024, are encouraged to contact the firm before November 12, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Taro’s Board entered into an agreement and plan of merger (the "Merger Agreement") with Sun Pharmaceutical Industries Ltd. ("Sun Pharma") on January 17, 2024. The Company’s Board then released a materially incomplete proxy statement on April 15, 2024. The proxy statement included incomplete information on the methodology and key assumptions used in valuation by BofA Securities, Inc. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Taro, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
